Tivic Health Systems Inc. Common Stock (TIVC)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-06-26, TIVC traded at $0.56 with a $3.3M market cap. The business description identifies it as Valion Bio, Inc., a late-stage immunotherapeutics company whose lead candidate, Entolimod, targets acute radiation syndrome, with Entolasta and CDMO services also in the mix. My first question is always whether there is a durable business underneath. Here, the filed 2025-Q4 quarter showed revenue of negative $302,000 and net income of negative $2.8M, with a 943.38% margin. That is not an operating business throwing off cash; trailing free cash flow was negative $11.2M, and the FairStock FCF yield is -343.9%, meaning the burn dwarfs the entire market value. The balance-sheet optics are odd: FairStock's P/B is 0.08 at the 2026-06-26 close, which might attract a Graham-style asset hunter. But book value at a cash-burning drug developer can vanish through losses. FairStock's P/E is -0.08 at the same close, plainly reflecting red ink. FairStock's ROE is -82.69% and ROCE is -28.69%, while debt-to-equity is 0.38. The FairStock Piotroski F-Score is 1/9, and FairStock Altman Z-Score is -2.08, both pointing to significant financial stress. Growth is equally unproven: there is no Lynch category because there are only 0 years of filed results, versus the 3 needed. A moat requires durable advantages and pricing power. I see no evidence of either. The value depends almost entirely on clinical and regulatory outcomes that are binary and outside my circle of competence. At a $3.3M market cap, it is a lottery ticket, not a Buffett-style compounding machine.

In plain English: The company, described in the data as Valion Bio, Inc., is a tiny healthcare developer working on immunotherapies for acute radiation syndrome and related conditions, with some contract development services. Its latest filed quarter showed negative revenue and a sizable loss, and it burns far more cash than its whole market value in a year. The stock price is very low, but because the business is losing money heavily and has negative revenue, it does not look like a conventional cheap bargain; it looks speculative.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-06-26 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer